This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Clinical Updates in the Management of Severe Asthma: New Strategies for Individualizing Long‐Term Care

Clinical Updates in the Management of Severe Asthma: New Strategies for Individualizing Long‐Term Care

Format

Interactive Monograph

Time to Complete

1 hour

Released

June 8, 2017

Expires

June 8, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Nurse Practitioners

Accredited Provider

This activity is jointly provided by Global Education Group and Integritas Communications.

Commercial Supporter

This activity is supported by an educational grant from AstraZeneca and Genzyme, a Sanofi company, and Regeneron Pharmaceuticals.

Program Description

An estimated 5% to 15% of the more than 25 million Americans with asthma have a severe form of the disease and are burdened by an outsized proportion of asthma-related morbidity, mortality, and healthcare costs.1,2  Although managing this cohort has historically been challenging, new insights into the heterogeneous clinical features and disease mechanisms among patients with severe asthma have raised the possibility of integrating presenting characteristics with molecular and cellular profiling to identify endotypes -- ie, phenotypic descriptions that are matched with underlying mechanistic pathways.3,4  Detailed disease classification, the development of biomarkers, and longitudinal monitoring of symptom control are now being used to guide the use of the growing number of biologic therapies, an important educational topic as pulmonologists and clinical immunologists increasingly seek to personalize treatment for patients with severe asthma.3,5,6  Available in multiple formats, this multimedia eHealth SourceTM will cover best practices for assessing disease control in patients with severe asthma, the evidence for current and emerging therapies, and strategies to improve patient education and treatment adherence.
___________________________________

References
1. Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015;11(1):14-24.
2. Bahadori K, et al. Economic burden of asthma: a systematic review. BMC Pulmonary Medicine. 2009;9:24.
3. Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373.
4. Lötvall J, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-360.
5. Wan XC, Woodruff PG. Biomarkers in severe asthma. Immunol Allergy Clin North Am. 2016;36(3):547-557.
6. Walsh GM. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma—an update. Expert Rev Clin Immunol. 2016 Aug 2:1-7. [Epub ahead of print]

Intended Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the ongoing management of patients with severe asthma.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss the pathophysiology of severe asthma, focusing on clinically relevant disease subtypes and molecular targets for new biologic medications
  • Comprehensively assess patients with symptoms of severe asthma to determine the level of disease control and uncover potential phenotypes that can guide ongoing therapy
  • Describe the clinical profiles of current and emerging biologic therapies for patients with severe asthma
  • Individualize long-term management regimens for patients with severe asthma based on current symptoms, past treatment responses, appropriate biomarkers, and exacerbation risks
  • Educate patients with severe asthma and, when necessary, their caregivers to facilitate shared decision making, encourage self-management, and promote treatment adherence

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, NJ

Dr. Panettieri discloses the following:
Consultant: AstraZeneca, Gilead, Johnson & Johnson, Merck, Teva, NIH
Grant/Research: AstraZeneca, Gilead, Johnson & Johnson, Merck, Roche, Sanofi-Aventis, Teva, NIH

Michael E. Wechsler, MD, MMSc
Co-Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
Denver, CO

Dr. Wechsler discloses the following:
Consultant: AstraZeneca, BSCI, Teva, Novartis, Sanofi-Aventis, Vectura Group, Sunovion, Regeneron, Ambit bioscience, Meda, Mylan, Gliacure, Tunitas, Genentech, Theravance

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Kristen Delisi, NP, has nothing to disclose.
Jim Kappler, PhD, has nothing to disclose.
Rose O’Connor, PhD, has nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global and Integritas. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024.

Designation Statement

This activity is approved for 1.00 contact hour(s) which includes 0.00 hour(s) of pharmacology.

Activity ID #2103E.

This activity was planned in accordance with AANP CE Standards and Policies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

In order to receive credit, participants must complete the pre-assessment, post-test, and program evaluation. Participants must also score at least a 70% on the post-test. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue